OCT 20, 2016 02:37 PM PDT

Compound in Common Cold Meds May Fight Bladder Cancer

WRITTEN BY: Xuan Pham

Could a compound found in common cold medicine stop the spread of bladder cancer? It sounds sensational, but that’s the suggestion from the results of a study conducted at Hokkaido University in Japan.
 

Image credit: Pixabay.com

Bladder cancer doesn’t get as much attention as other cancers, like breast, kidney, or prostate cancer. However, bladder cancer accounts for about 5% of all new cancer cases in the U.S., and it is the fourth most prevalent cancer in men. In 2016, the American Cancer Society estimates nearly 77,000 new bladder cancer cases, which may claim more than 16,000 lives.
 
Though some types of bladder cancer have good prognoses, some types are resistant to standard chemotherapy treatments, such as cisplatin. This increases the risks for metastasis, which severely diminishes the survival outcomes.
 
To find new drug targets for bladder cancer, the research team, led by Shinya Tanaka, turned to a mouse xenograft model. In particular, they inoculated mice with human bladder cancer cells and tracked the metastatic process. Then, the tumor samples were collected and analyzed with microarray analyses to determine which genes were abnormally expressed.
 
Using this system, the team zeroed in on the enzyme known as aldo-keto reductase 1C1 (AKR1C1), which was abnormally expressed as much as 25 times the normal levels. This abnormal expression was next confirmed in human bladder cancer samples, corroborating the involvement of AKR1C1 in the metastatic event.
 
Tumor growth in the xenograft bladder cancer model was monitored using a bioluminescence imaging system. Forty-five days after inoculation, metastatic tumors were detected in the lungs, liver and bone. (Matsumoto R. et. al., Scientific Reports, October 4, 2016)

Importantly, AKR1C1 levels don’t seem to be affected by anticancer drugs like cisplatin, the a well-known platinum-containing chemotherapy agent.
 
To block AKR1C1 signals, the team treated mice with a known inhibitor of this enzyme: flufenamic acid. Of note, flufenamic acid is a nonsteroid anti-inflammatory drug (NSAID) commonly used to treat colds and pains. The team found that flufenamic acid seemed to antagonize AKR1C1 and decreased the cisplatin-resistance, which amounted to reduced metastasis.
 


The authors conclude that, “These data uncover the crucial role of AKR1C1 in regulating both metastasis and drug resistance; as a result, AKR1C1 should be a potent molecular target in invasive bladder cancer treatment.”
 
The drug will next enter rigorous clinical trials to see if bladder cancer risks are minimized. However, one big advantage is that the drug is relatively common and inexpensive, making it an ideal candidate for a new cancer drug. "This latest research could pave the way for medical institutions to use flufenamic acid -- a much cheaper cold drug -- which has unexpectedly been proven to be effective at fighting cancers," said Tanaka.

Additional sources: MNTHokkaido University 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 19, 2019
Cancer
OCT 19, 2019
Vitamin A consumption decreases risk of skin cancer
We know that vitamin A is important for our bodies’ growth and development, in particular for eye, reproductive, and skin health. Now new research sh...
OCT 19, 2019
Cancer
OCT 19, 2019
Eat more flavonoids!
An apple a day keeps the doctor away? New research published in Nature Communications suggests that there might be some truth to that old saying. But it&rs...
OCT 19, 2019
Cancer
OCT 19, 2019
Early onset colorectal cancer on the rise
New research from the American Cancer Society and recently published in Gut shows that colorectal cancer in young adults is on the rise in high-income coun...
OCT 19, 2019
Cancer
OCT 19, 2019
Can eating mushrooms reduce the risk of prostate cancer?
Now here’s a question: have you eaten your mushrooms yet today? Although mushrooms may not be one of the typically-touted snacks in the healthcare wo...
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
OCT 19, 2019
Cell & Molecular Biology
OCT 19, 2019
Differences in Pediatric vs. Adult Cancer Force the Discussion of Effective Therapies
A team of scientists study the differences between childhood and adult cancer. This drives the discussion of the use of effective adult cancer treatments on children....
Loading Comments...